Moderna has started applying for emergency regulatory approval of its COVID-19 vaccine in the U.S. and Europe, saying its candidate has proven nearly 94.1 percent effective.
It also reported the vaccine's efficacy rate was consistent across age, race, ethnicity and gender demographics and had a 100 percent success rate in preventing severe symptoms.
The company explained Monday that it's filing for emergency use authorization from the U.S. Food and Drug Administration as well as conditional approval from the European Medicines Agency.
This will make Moderna's vaccine the second one likely to receive emergency use authorization in the U.S. this year, followed by Pfizer, which filed for the approval after confirming that its vaccine candidate is 95 percent effective.
The development comes as Washington's health secretary explained to CBS News that, if approved, vaccines could be available before Christmas.
He also added governors would be given the discretion to decide which segments of the population would be first in line to receive them.
UK Prime Minister Boris Johnson also hinted Monday that the vaccines could be available in a matter of weeks.
"And, you know, this could if we're lucky, if everything goes right, this could be available just in a few weeks. And this could - and I stress could - really be the salvation for humanity, these vaccines, not just this one, but obviously all the vaccines that are currently being developed."
He explained the UK is taking a so-called "twin approach," where the roll-out of the vaccine coincides with mass testing, enabling Britain to contain the virus, while opening up the economy at the same time.
Kim Hyo-sun, Arirang News.